Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L
about
Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substratesPro-urokinase-type plasminogen activator is a substrate for hepsinActivation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine proteaseThe urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodelingCathepsin L colocalizes with chromogranin a in chromaffin vesicles to generate active peptidesHighly potent inhibitors of human cathepsin L identified by screening combinatorial pentapeptide amide collections.Human cathepsin X: a novel cysteine protease of the papain family with a very short proregion and unique insertions.The plasmin cascade and matrix metalloproteinases in non-small cell lung cancerProteases Revisited: Roles and Therapeutic Implications in Fibrosis.Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages.Expression of cathepsin L and its inhibitor hurpin in inflammatory and neoplastic skin diseases.Cysteine peptidases of mammals: their biological roles and potential effects in the oral cavity and other tissues in health and disease.Cathepsins in Rotator Cuff Tendinopathy: Identification in Human Chronic Tears and Temporal Induction in a Rat ModelMicroenvironmental and cellular consequences of altered blood flow in tumours.Modulation of the tumor vasculature and oxygenation to improve therapySaturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer.Cathepsin L targeting in cancer treatment.Leukocyte cell surface proteinases: regulation of expression, functions, and mechanisms of surface localization.Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.Cathepsin L in metastatic bone disease: therapeutic implications.Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94.Proteinases and their inhibitors in liver cancer.Extracellular acidity, a "reappreciated" trait of tumor environment driving malignancy: perspectives in diagnosis and therapy.The acidic microenvironment as a possible niche of dormant tumor cells.Interleukin-6 and cyclic AMP stimulate release of cathepsin B in human osteoblasts.Transcription levels of invasion-related genes in prostate cancer cells are modified by inhibitors of tyrosine kinase.Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation.Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-betaL a process initiated by the exocytosis of cathepsin B.Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.Activation of thrombin-inactivated single-chain urokinase-type plasminogen activator by dipeptidyl peptidase I (cathepsin C).The biochemistry of cancer dissemination.Cathepsin B, cathepsin L, and cystatin C in the porcine uterus and placenta: potential roles in endometrial/placental remodeling and in fluid-phase transport of proteins secreted by uterine epithelia across placental areolae.Immunohistochemical localization of cathepsin L and cystatin A in normal skin and skin tumors.Epidermal growth factor-binding protein activates soluble and receptor-bound single chain urokinase-type plasminogen activator.Collagen degradation by interleukin-1beta-stimulated gingival fibroblasts is accompanied by release and activation of multiple matrix metalloproteinases and cysteine proteinases.Expression of cathepsin proteinases by mouse trophoblast in vivo and in vitro.Acidic pH as a physiological regulator of human cathepsin L activity.Mature and progenitor endothelial cells perform angiogenesis also under protease inhibition: the amoeboid angiogenesis.Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
P2860
Q22254229-CBB55211-9154-4A7E-AADA-FE25D58EC9EDQ24299743-7768BEA8-2953-4B87-811E-81F8E13BA974Q28144714-027B923F-44D9-4B8E-BDC9-948B94652461Q28257803-835E4A52-87D8-4506-A131-F51214D38480Q28579762-AEAAD12C-4FF8-4DE1-9FFB-DAD71AC7CE54Q30897474-0C8FC13B-5F60-4A27-9F3A-71C36F53F94DQ32021129-2EF1D6E9-7E1A-4CDA-8633-89F853F581B3Q33634208-628D3BB8-97F7-4608-BF01-337CF18FE1E1Q33795055-9B798F88-C0CB-42CC-8A95-8326D29F6E8CQ34385281-725F3724-44A8-4F3D-9DB0-3EABA35351F6Q34487589-BAA5AE61-22C6-4D67-BC15-7089CC37AE42Q34713891-14824371-2F47-4311-AB51-4A76B4E1C7C2Q35822911-39CF60E1-A46A-4AB1-873E-100BB249C76BQ35904989-46776204-5BA3-428C-8F13-5790A93BC986Q35920685-2C74B5C5-8BD2-4E5B-B940-628BF545E1DEQ35976072-3D2D6EFF-7D41-4BF2-89B4-55FDCCFCA2D4Q36031062-6D0102F7-66B6-4358-99F4-C8D61C9222E0Q36218199-C7E0FE1A-17F9-4A76-8C00-B3A6D63E9AEBQ36715904-15A7DEDC-DE00-4351-B5AA-5EDDFCB077F9Q36723297-4FD43BC6-4A21-43E5-9A8C-B89BF57E0094Q37724780-D4D6B7B4-F755-4ED0-A613-084848BD75BBQ37735722-450C8955-C914-4657-9AC0-CE1AB81E8B2AQ37821301-74639251-0027-45A5-99F5-8FD1DD099503Q38225316-7AF22605-F5C0-49F3-82E6-E80DB73AF4E0Q39195025-C2635E9D-88D9-4A8F-AFB3-DC51624FE4BBQ40082216-B0FF6A0E-2A3F-4353-BEFE-B8C2F0E39253Q40275334-93469FEF-44A4-4ADC-BEF4-AF6DFA72F8A8Q40293146-F32ADF9D-BFC7-4B20-9805-6614FEE58AB8Q40754112-C121BF89-5EC4-4BDB-ADF2-3C6F286ECA63Q40942602-B262E980-B300-4FF0-BFB2-8E4263AD13FFQ41454363-9D941906-4A15-45E8-9768-A92AF5FDC144Q41547351-DB0D5590-796E-43D8-9DC2-B782014E3222Q43182511-9606E614-5153-452C-B7C4-5FB739B05AF8Q44188228-FE1108B6-FF94-4A48-B49D-1484350A3D6DQ46333843-81CD046A-6384-4214-96A6-520273A0FBEEQ46877423-C6D22682-86A1-41C8-935D-9CC4AEC5A300Q52171774-2B173000-E22A-40D6-8304-C29FC01098D3Q52534368-43221BFB-0E7B-46E4-B81B-E44172A594D2Q54936719-CF11BBC1-A4F5-48F8-9DC9-ADD084B59361Q54960825-98B76628-3D55-49E4-B9D4-BD58E07191F0
P2860
Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L
description
1992 nî lūn-bûn
@nan
1992 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Effective activation of the pr ...... cysteine protease cathepsin L
@ast
Effective activation of the pr ...... cysteine protease cathepsin L
@en
Effective activation of the pr ...... cysteine protease cathepsin L
@nl
type
label
Effective activation of the pr ...... cysteine protease cathepsin L
@ast
Effective activation of the pr ...... cysteine protease cathepsin L
@en
Effective activation of the pr ...... cysteine protease cathepsin L
@nl
prefLabel
Effective activation of the pr ...... cysteine protease cathepsin L
@ast
Effective activation of the pr ...... cysteine protease cathepsin L
@en
Effective activation of the pr ...... cysteine protease cathepsin L
@nl
P2093
P2860
P1433
P1476
Effective activation of the pr ...... cysteine protease cathepsin L
@en
P2093
L Goretzki
N Chucholowski
W A Günzler
P2860
P304
P356
10.1016/0014-5793(92)80339-I
P407
P577
1992-02-01T00:00:00Z